Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback